Summary Quantitation of metabolic changes in tumours may provide an objective measure of clinical and subclinical response to anticancer therapy. This pilot study assesses the value of quantitation of metabolic rate of glucose (MRGlu) measured in mmol min -1 ml -1 to assess early subclinical response to therapy in a relatively non-responsive tumour. Nine patients receiving the CRC Phase II study schedule of temozolomide were assessed with [ -2 over 5 days every 28 days. Tumour MRGlu was calculated and compared with objective response at 8 weeks. Pretreatment MRGlu was higher in responders than non-responders. The responding patient group had a greater than 25% reduction in MRGlu in regions of high focal tumour uptake (HFU). Whole tumour changes in MRGlu did not correlate with response. Percentage change in HFU standardized uptake value (SUV) did discriminate the responding from the non-responding patients, but not as well as with MRGlu. Large differences also occurred in the normal brain SUV following treatment. Thus, MRGlu appeared to be a more sensitive discriminator of response than the simplified static SUV analysis. Changes in MRGlu may reflect the degree of cell kill following chemotherapy and so may provide an objective, quantitative subclinical measure of response to therapy.
The ability to assess tumour response after a single cycle of chemotherapy may improve patient management and early evaluation of new anticancer therapies. Quantitative tumour metabolic response rate assessment has been suggested as a surrogate end point for tumour response to therapy and may assist in the identification and scheduling of new chemotherapeutic strategies in phase I and II clinical trials (Price and Jones, 1995) . Clinically, early identification of those patients with non-responding tumours may permit the cessation of ineffective therapy and promote individualization of therapy.
Positron emission tomography (PET) is an in vivo functional imaging modality using positron-emitting radiolabelled compounds. The most widely used radiotracer in oncology is 2-[ 
]FDG-6-P). It effectively becomes 'trapped' intracellularly since dephosphorylation is slow especially in tissues with low levels of glucose-6-phosphatase. [ 18 F]FDG uptake is enhanced in tumours due to both increased transport and phosphorylation (Bennett et al, 1978; Herholz et al, 1992; Brown et al, 1993 Brown et al, , 1996 . Increased [ 18 F]FDG uptake, as measured by PET, although a function of proliferative activity (Minn et al, 1988a; Okada et al, 1992; Higashi et al, 1993 ) is related to the number of viable tumour cells . Therefore, reduction in the viable tumour cell population with effective chemotherapy should result in reduced [ 18 F]FDG uptake. A number of pilot studies have shown that early reduction in tumour [ 18 F]FDG uptake is related to tumour response to effective chemotherapy in extracerebral tumours (Minn et al, 1988b; Ichiya et al, 1991; Wahl et al, 1993; Jansson et al, 1995) . Pilot studies with intracerebral tumours have shown reduced tumour [ 18 F]FDG uptake corresponding with radiological improvement and therapeutic response duration in patients with medulloblastoma (Holthoff et al, 1993) . For patients with gliomas, reduction in tumour [ 18 F]FDG uptake corresponded with radiological response 30 days after combination chemotherapy (Rozental et al, 1989) and with patient survival (De Witte et al, 1994) .
Assessment of alterations in tumour extent with therapy using computerized tomography (CT) and magnetic resonance imaging (MRI) can be a problem for gliomas where the tumour can not be clearly delineated from post-operative enhancement (Cairncross et al, 1985) and radiation-induced necrosis and prognosis (Alavi et al, 1988 (Valk et al, 1988) . It has been proposed that changes in [
18 F]FDG uptake could be used to parallel phase I and II clinical trials (Price and Jones, 1995) to provide an objective quantitative measure of clinical and subclinical response.
Temozolomide is a methylating imidazotetrazinone which was evaluated during a phase II clinical trial at Charing Cross Hospital, London, under the auspices of the Cancer Research Campaign's (CRC) Phase I & II Clinical Trials Committee. The initial phase I trial had previously demonstrated that the drug had activity against gliomas, malignant melanoma and mycosis fungoides on a five day schedule repeated every 28 days, with myelosuppression being the main toxicity (Newlands et al, 1992; O'Reilly et al, 1993) .
The aim of this pilot study was to evaluate [ 18 F]FDG-PET as an early tumour metabolic response marker in high-grade gliomas treated with the phase II treatment schedule of temozolomide.
MATERIALS AND METHODS

Patients
Nine patients with recurrent grade III and IV gliomas being treated using the CRC Phase II trial schedule of temozolomide were recruited for the [ 18 F]FDG-PET study. Eligibility criteria included those for entry into the phase II clinical study (O'Reilly et al, 1993) and the ability to undergo two PET scans. No patient had received radiotherapy or chemotherapy in the 4 weeks preceding treatment with temozolomide, or in the preceding 6 weeks for those who had received treatment with nitrosoureas. All had evaluable tumour on CT scan and had WHO performance status of ≤3.
Temozolomide was administered at a dose of 750 mg m -2 divided equally over 5 days for the first cycle, increased to 1000 mg m -2 divided over 5 days for the subsequent cycles providing there had been no myelosuppression noted on day 22. The cycles were repeated every 28 days (O'Reilly et al, 1993 (Lindholm et al, 1993; Ishizu et al, 1994) . For those receiving corticosteroids, dexamethasone dosage was stabilized for a minimum of 2 weeks prior to performing the baseline scans and initiating temozolomide to minimize changes in oedema induced by steroid administration (Cairncross et al, 1988) . There was no alteration in the patients' dose of corticosteroids nor anticonvulsant medication until at least after the second [
18 F]FDG-PET study. This is important as dexamethasone can elevate circulating plasma glucose levels which may confound the interpretation of SUV and K 1 (Roelcke et al, 1998) and it has also been shown to decrease normal cerebral glucose metabolism (Fulham et al, 1995) .
[ 18 F]FDG was synthesized on-site at the MRC Cyclotron Unit, using the stereospecific reaction consisting of a nucleophilic fluorination followed by a de-protection stage to produce a no-carrier added FDG (Hamacher et al, 1986 18 F]FDG and glucose concentrations. All image data were acquired on an ECAT 953B CTI Neuro-PET scanner (CTI/Siemens, Knoxville, TN, USA). The patients were positioned using a head support and the orbito-meatal line parallel to the transaxial plane of the tomograph, such that the tumour position was well within the 10.8 cm field of view. Prior to the [ The rate constants K 1 , k 2 , k 3 and k 4 are determined using kinetic modelling and characterize delivery, washout, phosphorylation and dephosphorylation respectively. The original three compartment model (Sokoloff et al, 1977) has been extended to include a dephosphorylation rate constant (k 4 ) of the reaction [
The [
18 F]FDG was injected as an intravenous bolus given over a 30 s period starting 30 s into the [
18 F]FDG-PET study. The patient's radial arterial blood was continuously withdrawn over a calibrated bismuth germinate (BGO) detector allowing continuous measurement of arterial radioactivity (Ranicar et al, 1991) . Downstream from the detector discrete samples were taken immediately prior to the start of the scan and at 5, 10, 20 and 50 min. These samples were used to measure circulating glucose levels and partition [
18 F] radioactivity between whole blood and plasma.
PET data analysis
The PET data were attenuation corrected and reconstructed using filtered back projection with a Hann filter, cut off at the Nyquist frequency (8.2 ± 0.2 mm), into two-dimensional matrices of 128 × 128 with pixel dimensions of 2.016 × 2.016 mm. The 31 slices were stacked to form a three-dimensional volume with an axial slice width of 3.375 mm. The second [ 18 F]FDG-PET study was co-registered to the first using the Wood's algorithm (Woods et al, 1992) . All frames for each study were summed to provide an image of higher statistical quality for region of interest (ROI) drawing. ROI analysis was performed using the Sunview package 'Analyze' (Analyze, Mayo Clinic, Rochester, MN, USA).
Region of interest definition
Gliomas are heterogeneous structures containing oedema, scar tissue, necrosis as well as viable tumour cells. Clear delineation of the tumour margins from normal brain tissue and peripheral oedema can prove difficult using anatomical imaging. In this study, ROIs were defined with visual reference to a pretreatment CT scan to assist in the anatomical localization of tumour extent. Normal brain (B) was defined as uninvolved contralateral temporo-parietal white matter, whole tumour (WT) defined a region encompassing the whole tumour and high focal [ 18 F]FDG uptake areas (HFU) were defined as a small area within the tumour with the highest uptake defined visually. ROIs for all three tissue areas are defined on the baseline [
18 F]FDG-PET study. Co-registration of second to the first [
18 F]FDG PET study was employed (Woods et al, 1992) . Tissue time activity curves were generated by applying the ROIs defined to the co-registered dynamic PET scan frames for both studies. The average count per pixel was used for each ROI. Where it was possible to define more than one HFU, the one with the highest MRGlu at baseline was used for comparison.
Calculation of MRGlu
The [ 18 F]FDG plasma time concentration curve was generated from the continuous and discrete arterial blood samples to provide an input function. The metabolic rate for glucose (MRGlu µmol min -1 ml -1 ) was determined using the arterial input function, and the PET-generated tissue time activity curves with a three compartment model (Figure 1) .
The tissue or tumour glucose utilization rate is given by:
The K values are the rate constants as defined in Figure 1 . The lumped constant (LC) corrects for differences in the transport and phosphorylation rates of FDG and glucose, and is defined as the ratio of the FDG phosphorylation rate to the rate of glucose phosphorylation. It was set to 0.52 as previously measured for normal brain tissue (Reivich et al, 1985) . C pl is the plasma glucose concentration (µmol ml -1 ). Due to technical failure, the plasma glucose concentration measured at 50 min was not available for some studies (n = 4 patients; 6 studies). No significant difference was seen between the available whole blood and plasma glucose concentrations measured at 20 min (n = 11, mean difference ± standard deviation (s.d.): 0.07 ± 0.44; t-test P > 0.2, t = 0.05) (Bland and Altman, 1986) . The 20 min whole blood glucose concentrations were used to compute MRGlu for this study.
Calculation of standardized uptake values
In addition to calculating the glucose utilization rates for the regions defined, standardized uptake values (SUV) were also measured thereby allowing comparison of the two analysis methods. Standardized uptake values are a simplified model independent, semi-quantitative technique. It would be an easier calculation for clinical work being undertaken in busy nuclear medicine departments. It utilizes a static image, in these studies determined from the last 15 min of the scan, and normalizes it for known differences between the studies, i.e. patient weight or body surface area and injected activity of [
18 F]FDG.
Clinical response assessment
Contrast-enhanced CT scans and MRC neurological status assessment (Table 1) were performed pretreatment and after two courses No useful function -inability to make conscious responses. MRGlu (µmol min -1 ml -1 ) = C pl × K 1 k 3 LC k 2 + k 3 of temozolomide (8 weeks). For assessment of tumour response in high-grade glioma, objective response (OR) was used. This requires an improvement in the MRC neurological status by one grade and a clear-cut reduction in mass effect radiologically with a minimum duration of 4 weeks and no development or deterioration in other neurological symptoms or signs (Bleehen et al, 1989) . Objective response was defined at 8 weeks. For analysis patients with stable and progressive disease were classified as non-responders.
RESULTS
Details of patients are summarized in Table 2 . All nine patients had received radiotherapy as their primary treatment (median 15 months previously; range 3.3-60.7 months). One (no. 4) had received adjuvant chemotherapy (temozolomide) combined with radiotherapy 2 years previously. All patients had normal liver and renal function prior to therapy and none had known diabetes mellitus. One patient (no. 8) had the second PET scan delayed until after the second course of temozolomide due to illness. The mean circulating whole blood glucose concentration at 20 min was (5.6±0.56 mmol l -1
). Clinical response was available in all eight treated patients. Four patients had an objective response, two stable disease and two progressive disease at 8 weeks. The control patient was not assessed for clinical objective response. ) for normal brain 
sampled contained a varying number of pixels since active tumours themselves are of varying sizes. Brain mean 223 pixels (range 113-432 pixels n = 9); whole tumour, mean 1087 pixels (range 264-2673 pixels; n = 9); high focal tumour uptake, mean 48 pixels (range 9-106 pixels; n = 9). For the control patient (no. 1) the percentage changes determined for sampled tissue regions were -8% for normal brain, +4% for whole tumour and -10% for the high uptake focus within the tumour.
Normal brain MRGlu was not significantly altered by treatment with temozolomide (n = 9, P > 0.2 t-test) (Figure 2 ). Following temozolomide, the MRGlu for the whole tumour (WT) regions was decreased in three patients and increased in five patients. Alterations in whole tumour MRGlu did not consistently correspond with an objective response assessed at 8 weeks (Figure 3) .
A greater than 25% reduction in [
18 F]FDG uptake in the HFU regions was seen in four patients (nos 5-8). In the other four patients there was either no change or an increase in the MRGlu for the high focal uptake areas (nos 2, 3, 4, 9). Figure 4 shows the relationship between percentage change in MRGlu for HFU regions responding and non-responding patients. Those patients with 25% reduction in MRGlu at 14 days in HFU regions achieved an objective response at 8 weeks (n = 4).
Pretreatment MRGlu levels in HFU were found to be related to response, being higher in the responding patient group. There was no difference between responders and non-responders in pre-or post-treatment normal brain MRGlu values or in absolute change in MRGlu.
Comparison of the MRGlu with SUV analysis for individual ) and standardized uptake values (SUV) for all tissue and tumour regions patients for B, WT and HFU is shown in Figure 5 . There were differences in normal brain SUV values following treatment with temozolomide ( Figure 6 ). Comparison of percentage change in SUV following treatment with response category for both WT and HFU is shown in Figure 7 and 8 respectively. WT regions were not able to discriminate responders from non-responders. Percentage change in HFU regions was better at discriminating, but not as good as using MRGlu.
DISCUSSION
In this study, reduction in MRGlu of > 25% in regions of HFU was seen 14 days after one cycle of temozolomide in patients who went on to have a objective response at 8 weeks.
Alterations in whole tumour MRGlu did not correspond with objective response. Despite visual comparison with anatomical imaging, whole tumour regions sampled may contain normal brain tissue, fibrosis, cystic fluid and oedema in addition to viable tumour cells. The MRGlu for whole tumour regions therefore may be, in part, determined by these non-tumour elements and will not be as affected by anti-proliferative chemotherapy as viable tumour. [
18 F]FDG uptake is increased in viable tumour and regions of HFU probably contain a higher proportion of viable tumour cells.
Responding tumours had higher pretreatment MRGlu values in HFU regions. A high MRGlu is usually associated with more aggressive tumours , suggesting that these may be more responsive to temozolomide treatment.
Blood-brain barrier disruption can alter the hexose transport system and allow passive diffusion of glucose and [
18 F]FDG into brain tumours. It is unknown by how much or how quickly the integrity of the blood-brain barrier improves with response to therapy. However, independence of deoxyglucose utilization and blood-brain barrier disruption have been demonstrated in an animal glioma model (Blasberg et al, 1981) . Alternations in tumour [
18 F]FDG uptake were measured early in the course of treatment and probably reflect alterations in tumour [
18 F]FDG utilization rather than changes in blood-brain barrier integrity.
As environmental conditions were not controlled for auditory and visual stimuli, the temporo-parietal brain was selected as a reference region for normal brain in this study. The variation in normal brain MRGlu was not significant within the precision of the measurement and therefore not attributable to treatment or environmental stimulation.
There is controversy over the optimal method to assess (Phelps et al, 1979 ) and the original model (Sokoloff et al, 1977) extended to include a dephosphorylation (k 4 ) rate constant (Phelps et al, 1979; Huang et al, 1980) . It is thought that extrapolation of normal tissue data to tumours may not be entirely accurate since the model assumes tissue homogeneity (Herholz et al, 1990; Schmidt, 1992) . The lumped constant for brain tumour has not yet been established (Fischman and Alpert, 1993) . The lumped constant (LC 0.52) used in this study has been derived for normal brain (Reivich et al, 1985) . Values derived for normal brain range from 0.42 to 0.86 (Phelps et al 1979; Reivich et al, 1985; Lammertsma et al, 1987) and where values have been reported for tumour they range from 0.72 to 3.10 (Spence et al, 1998) . The absence of a consistent value for the lumped constant for tumour is a limitation for determination of MRGlu using [ Standardized uptake values offer an alternative for the simplification of tumour [
18 F]FDG uptake measurement and have previously been used in tumour response monitoring studies . However, there are some disadvantages. SUV have been found to be positively correlated with body weight, due to reduced distribution of [ 18 F]FDG in the fat. Also, the underlying assumption that [ 18 F]FDG uptake is complete and irreversible at 60 min, the usual measurement time, is not usually fulfilled. Thus, measurement is often made in the initial uptake phase Hamberg et al, 1994) . The differences demonstrated in normal brain SUV following treatment and the inability of changes in [ 18 F]FDG SUV to descriminate responders from non-responders as well as MRGlu suggests that the SUV measurement may be a less robust assessment for changes in tumour post-treatment. Brain tumour response is usually a small change and so the most sensitive measure is required to detect important small changes.
An assessment of the benefit of this method over simplified quantitation methods, e.g. SUV analysis, in terms of sensitivity and specificity warrants further assessment in studies specifically designed to address these issues.
The numbers for this pilot study are small and one control patient provides an indication, but not a measure of analysis technique reproducibility. Subsequent reproducibility [
18 F]FDG PET studies are underway, of which currently three pairs have been performed. Similarly, a variation of < 6.5% for normal brain and < 10.3% for whole tumour has been measured (Brock et al, unpublished data) .
In this pilot study [ 18 F]FDG-PET functional imaging provided a sensitive and quantitative measure of early tumour response to chemotherapy. The efficacy of this technique for quantifying degree of response is currently under evaluation in a larger group of patients with high-grade glioma receiving treatment with temozolomide, radiotherapy or a combination of the two. This will also define a more objective threshold value for the prediction of tumour response.
